Cytokine dermatitis and febrile seizure from imiquimod

Pediatrics

Volumn 129, Issue 2, 2012, Pages

  Mosher, J Suzanne ^a   Lio, Peter ^b  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adverse effect; Carcinoma; Fever; Imiquimod; Immunomodulator; Keratosis; Seizure; Toll like receptor 7; Topical

Indexed keywords

CEFALEXIN; IMIQUIMOD; NYSTATIN;

ARTICLE; CANDIDIASIS; CASE REPORT; CELLULITIS; CHILD; CLINICAL FEATURE; CYTOKINE DERMATITIS; DERMATITIS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEBRILE CONVULSION; FEMALE; FEVER; FOLLOW UP; HUMAN; MOLLUSCUM CONTAGIOSUM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN EXAMINATION; SOMNOLENCE; TONIC CLONIC SEIZURE; VOMITING;

ABDOMEN; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; CHILD, PRESCHOOL; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; GROIN; HUMANS; INTERFERON INDUCERS; MOLLUSCUM CONTAGIOSUM; SEIZURES, FEBRILE;

EID: 84856514509     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-0936     Document Type: Article

References (33)

1. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50(5):714-721 (Pubitemid 38580548)
2. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-733 (Pubitemid 38580549)
3. Holdiness MR. Contact dermatitis from topical antiviral drugs. Contact Dermat. 2001;44(5):265-269 (Pubitemid 32336997)
4. Campanelli A, Krischer J, Saurat JH. Topical application of imiquimod and associated fever in children. J Am Acad Dermatol. 2005;52(1):E1 (Pubitemid 40038926)
5. Shakil AO, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. J Hepatol. 1996;24(1):48-51 (Pubitemid 26037205)
6. Woynarowski M, Socha J. Seizures in children during interferon alpha therapy. J Hepatol. 1997;26(4):956-957 (Pubitemid 27145726)
7. Caksen H, Odabas D, Anlar O, Atas B, Tuncer O. Onset of generalized seizures after intrathecal interferon therapy of SSPE. Pediatr Neurol. 2003;29(1):78-79 (Pubitemid 37117185)
8. Pavlovsky L, Seiffert E, Heinemann U, Korn A, Golan H, Friedman A. Persistent BBB disruption may underlie alpha interferon-induced seizures. J Neurol. 2005;252(1):42-46
9. Virta M, Hurme M, Helminen M. Increased frequency of interleukin-1beta (-511) allele 2 in febrile seizures. Pediatr Neurol. 2002;26(3):192-195 (Pubitemid 34296531)
10. Bender RA, Dubé C, Baram TZ. Febrile seizures and mechanisms of epileptogenesis: insights from an animal model. Adv Exp Med Biol. 2004;548:213-225 (Pubitemid 38979624)
11. Mazarati AM. Cytokines: a link between fever and seizures. Epilepsy Curr. 2005;5(5):169-170
12. Syed TA, Goswami J, Ahmadpour OA, Ahmad SA. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol. 1998;25(5):309-313 (Pubitemid 28287665)
13. Theos AU, Cummins R, Silverberg NB, Paller AS. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis. 2004;74(2):134-138, 141-142
14. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27(7):571-577 (Pubitemid 35463873)
15. Barton JC. Angioedema associated with imiquimod. J Am Acad Dermatol. 2004;51(3):477-478
16. Lin R, Ladd DJ, Jr,Powell DJ, Way BV. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004;140(7):889-890 (Pubitemid 38917868)
17. Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol. 2005;141(7):908-909, author reply 909
18. Chakrabarty AK, Mraz S, Geisse JK, Anderson NJ. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol. 2005;52(2 suppl 1):35-37
19. Zalaudek I, Petrillo G, Argenziano G. Aphthous ulcers and imiquimod. J Am Acad Dermatol. 2005;53(2):360-361
20. Marty CL, Randle HW, Walsh JS. Eruptive epidermoid cysts resulting from treatment with imiquimod. Dermatol Surg. 2005;31(7 pt 1):780-782, discussion 782-783
21. Brown T, Zirvi M, Cotsarelis G, Gelfand JM. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52(4):715-716 (Pubitemid 40585458)
22. Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol. 2006;31(1):140-141
23. Benson E. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol. 2004;45(2):123-124 (Pubitemid 38607927)
24. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. N Z Med J. 2005;118(1223):U1682
25. Toyofuku K, Imayama S, Yasumoto S, Kiryu H, Hori Y. Clinical and immunohistochemical studies of skin eruptions: relationship to administration of interferon alpha. J Dermatol. 1994;21(10):732-737 (Pubitemid 24367502)
26. Yi BA, Nirenberg MJ, Goldstein SM, Berger TG. Chronic neuropathic pain associated with imiquimod: report of 2 cases. J Am Acad Dermatol. 2005;52(2 suppl 1):57-58
27. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547-555 (Pubitemid 39278073)
28. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141(4):467-473 (Pubitemid 40547405)
29. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15(5):374-381 (Pubitemid 41337416)
30. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939-947 (Pubitemid 40704934)
31. Garland SM, Sellors JW, Wikstrom A, et al Imiquimod Study Group. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts - results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS. 2001;12(11):722-729 (Pubitemid 33035830)
32. Adverse Event Reporting System Database AERS ISR # 4635713-X. Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4399b1- 30%20(Aldara%20(imiquimod)%20Safety%20Review).pdf. Accessed December 5, 2011
33. Adverse Event Reporting System Database AERS ISR # 3563013-8, US. Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4399b1- 30%20(Aldara%20(imiquimod)%20Safety%20Review).pdf. Accessed December 5, 2011